Objective: Uterine fibroids are the most common benign tumor in women and a specific treatment is not available. The combination of epigallocatechin gallate (EGCG), vitamin D and B6 in treating uterine fibroids (UFs) recently showed a promising efficacy. Here we tried to evaluate the efficiency of the combination to improve gynaecologycal and cardiological parameters.

Patients and Methods: 43 women with a diagnosis of UF were enrolled and divided into two groups: a) study group, treated twice a day with 150 mg EGCG, 25 µg vitamin D and 5 mg vitamin B6, for 4 months; b) control group, with no intervention. Volume, number of UFs, menstrual bleeding, pelvic discomfort, anemia and hypertension were monitored and analyzed.

Results: One UF developed in the control group, but none in the treated group. UF size significantly decreased from 10.73 ± 5.52 cm³ at baseline to 7.98 ± 4.00 cm³ after 4 months of treatment (p < 0.0001), while it remained unchanged in the control group (10.21 ± 5.83 cm³ at T0 to 10.62 ± 6.28 cm³ at T1). Menstrual bleeding and anemia ameliorated only in the treated women.

Conclusions: Supplementation with EGCG, vitamin D and B6 is a safe and novel approach for the management of UFs, reducing volume and improving menstrual bleeding and anemia of women presenting such symptoms.